Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440280 · ClinicalTrials.gov registry record · Phase 2
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
A Phase 2 study of Fuchs Endothelial Corneal Dystrophy, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04440280 is a Phase 2 study of Fuchs Endothelial Corneal Dystrophy that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 45 participants, below the 52-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04440280, a Phase 2 study of Fuchs Endothelial Corneal Dystrophy, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Conditions Studied
Interventions
- DRUG N-acetyl cysteine (NAC) 10% solution
- DRUG N-acetyl cysteine (NAC) 20% solution
- DRUG Visine Dry Eye Relief eye drops
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04440280
The ClinicalTrials.gov registry entry for NCT04440280 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52-participant average among 3 other Fuchs Endothelial Corneal Dystrophy trials with a reported enrollment target (13% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fuchs Endothelial Corneal Dystrophy appearing as the primary indexed condition, and to 3 interventions - of which N-acetyl cysteine (NAC) 10% solution is the first listed.
NCT04440280 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04440280 about?
NCT04440280 is a clinical study titled "Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy". This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
What is the current status of trial NCT04440280?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-09-16. Estimated completion is 2027-04-30.
What conditions does trial NCT04440280 study?
This clinical trial studies the following conditions: Fuchs Endothelial Corneal Dystrophy.
What interventions are being tested in trial NCT04440280?
The interventions under investigation include: N-acetyl cysteine (NAC) 10% solution (DRUG), N-acetyl cysteine (NAC) 20% solution (DRUG), Visine Dry Eye Relief eye drops (DRUG).
Who is sponsoring clinical trial NCT04440280?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04440280 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fuchs Endothelial Corneal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
RECRUITING · Phase 2
-
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.